5-cyclopentyl-2,3,4,5-tetrahydro-2-[(5-methyl-1 H-imidazol-4-yl)-methyl]-1 H-pyrido[4,3-b]indol-1-one | 122852-36-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 5-cyclopentyl-2,3,4,5-tetrahydro-2-[(5-methyl-1 H-imidazol-4-yl)-methyl]-1 H-pyrido[4,3-b]indol-1-one
• 英文别名: 5-cyclopentyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-3,4-dihydropyrido[4,3-b]indol-1-one
• CAS: 122852-36-2
• 化学式: C₂₁H₂₄N₄O
• 分子量: 348.448
• InChiKey: QKONBGHYUPYPDL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  26
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  53.9
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• [EN] THERAPEUTIC USE OF 5-HT3 RECEPTOR ANTAGONISTS
  申请人：SANDOZ AG

  公开号：WO1990012569A1

  公开（公告）日：1990-11-01

  (EN) 5-HT3 Receptor antagonists are useful in treating panic disorders and/or agoraphobia or obsessive compulsive disorders.(FR) Les antagonistes du récepteur 5-HT3 sont utiles pour traiter les troubles paniques et/ou l'agoraphobie ou les psychonévroses obsessionnelles.

  (EN) 5-HT3受体拮抗剂在治疗恐慌症和/或广场恐惧症或强迫症方面很有用。(FR) Les antagonistes du récepteur 5-HT3 sont utiles pour traiter les troubles paniques et/ou l'agoraphobie ou les psychonévroses obsessionnelles. (中文) 5-HT3受体拮抗剂对于治疗恐慌症和/或广场恐惧症或强迫症非常有用。
• NEW 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLE COMPOUNDS AND METHODS OF USE THEREOF
  申请人：Hung David T.

  公开号：US20100022580A1

  公开（公告）日：2010-01-28

  This disclosure relates to new tricyclic compounds that may be used to modulate a histamine receptor in an individual. Compounds are described, including new 2,3,4,5-tetrahydro- 1 H-pyrido[4,3-b]indole compounds. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.

  本公开涉及新的三环化合物，可用于调节个体中的组胺受体。其中描述了化合物，包括新的2,3,4,5-四氢-1H-吡啶[4,3-b]吲哚化合物。还提供了包含该化合物的制药组合物，以及使用该化合物治疗各种治疗应用的方法，包括治疗认知障碍、精神病性障碍、神经递质介导的障碍和/或神经元障碍。
• 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLE COMPOUNDS AND METHODS OF USE THEREOF
  申请人：Medivation Technologies, Inc.

  公开号：US20130190347A1

  公开（公告）日：2013-07-25

  This disclosure relates to new tricyclic compounds that may be used to modulate a histamine receptor in an individual. Compounds are described, including new 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole compounds. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.

  本公开涉及新的三环化合物，可用于调节个体中的组胺受体。其中包括新的2,3,4,5-四氢-1H-吡啶[4,3-b]吲哚化合物。此外还提供了包含这些化合物的制药组合物，以及使用这些化合物治疗各种治疗应用的方法，包括治疗认知障碍、精神障碍、神经递质介导的障碍和/或神经元障碍。
• NEW 2,3,4,5-TETRAHYDRO-1H-PYRIDO [4,3-B] INDOLE COMPOUNDS AND METHODS OF USE THEREOF
  申请人：MEDIVATION TECHNOLOGIES, INC.

  公开号：US20130190348A1

  公开（公告）日：2013-07-25

  This disclosure relates to new tricyclic compounds that may be used to modulate a histamine receptor in an individual. Compounds are described, including new 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole compounds. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.

  本披露涉及新的三环化合物，可用于调节个体中的组胺受体。本文描述了包括新的2,3,4,5-四氢-1H-吡啶[4,3-b]吲哚化合物在内的化合物。还提供了包括该化合物的药物组合物，以及使用该化合物在各种治疗应用中的方法，包括治疗认知障碍、精神障碍、神经递质介导的障碍和/或神经元障碍。
• Use of serotonin antagonists in the treatment of cognitive disorders
  申请人：GLAXO GROUP LIMITED

  公开号：EP0357415A2

  公开（公告）日：1990-03-07

  The invention relates to the use of compounds of formula wherein Im represents an imidazolyl group of formula: and R¹ represents a hydrogen atom or a group selected from C₁₋₆alkyl, C₃₋₆alkenyl, C₃₋₁₀alkynyl, C₃₋₇cycloalkyl,C₃₋₇cycloalkylC₁₋₄alkyl, phenyl, phenylC₁₋₃alkyl, phenylmethoxymethyl, phenoxyethyl, phenoxymethyl, -CO₂R⁵, -COR⁵, -CONR⁵R⁶ or -SO₂R⁵ (wherein R⁵ and R⁶, which may be the same or different, each represents a hydrogen atom, a C₁₋₆alkyl or C₃₋₇cycloalkyl group, or a phenyl or phenylC₁₋₄alkyl group, in which the phenyl group is optionally substituted by one or more C₁₋₄alkyl, C₁₋₄alkoxy or hydroxy groups or halogen atoms, with the proviso that R⁵ does not represent a hydrogen atom when R¹ represents a group -CO₂R⁵ or -SO₂R⁵); one of the groups represented by R², R³ and R⁴ is a hydrogen atom or a C₁₋₆alkyl, C₃₋₇cycloalkyl, C₃₋₆alkenyl, phenyl or phenylC₁₋₃alkyl group, and each of the other two groups, which may be the same or different, represents a hydrogen atom or a C₁₋₆ alkyl group; and n represents 2 or 3, and physiologically acceptable salts and solvates thereof for the manufacture of a medicament for the treatment of a cognitive disorder.

  本发明涉及式化合物的用途 其中 Im 代表式中的咪唑基团： 且 R¹ 代表氢原子或选自 C₁₋₆烷基、C₃₋₆烯基、C₃₋₁₀alkynyl、C₃₋₇cycloalkyl,C₃₋₇cycloalkylC₁₋₄alkyl、苯基的基团、苯基、C₁₋₃烷基、苯甲氧基甲基、苯氧基乙基、苯氧基甲基、-CO₂R⁵、-COR⁵、-CONR⁵R⁶或-SO₂R⁵（其中R⁵ 和R⁶可以相同或不同、各自代表氢原子、C₁₋₆烷基或 C₃₋₇环烷基，或苯基或苯基 C₁₋₄ 烷基，其中苯基任选被一个或多个 C₁₋₄ 烷基取代、C₁₋₄烷氧基或羟基或卤素原子取代，但当 R¹ 代表-CO₂R⁵或-SO₂R⁵基团时，R⁵不代表氢原子；） R²、R³和R⁴所代表的基团之一是氢原子或C₁₋₆烷基、C₃₋₇环烷基、C₃₋₆烯基、苯基或苯基 C₁₋₃烷基，而另外两个基团（可以相同或不同）分别代表氢原子或 C₁₋₆烷基； n 代表 2 或 3、 及其生理上可接受的盐和溶液，用于制造治疗认知障碍的药物。